

## الشركة الأولى للبحث والتطوير الصيدلاني ذ.م.م.

The First For Pharmaceutical Research & Development L.L.C.

# Test Report "Certificate of Analysis"

Report No.: TR-092-25

Rev: 00

Date: 11/03 /2025

Customer: Techno Orbits

Customer contact information: 079006582 Sample Description: MicroSure wound care

Receiving Date: 23/02/2025

Receiving condition/sample status:Ok

\*Deviation: NA

Testing location: InterPharma Lab, Sports City Area

Customer Reference: RC/027/25

Sample Code: S02/RC/027/25

Batch No.: H25000301

Expiry Date: 02/2027

TEST PERFORMED: EN 13624(yeasticidal activity) + EN13727 (bactericidal activity)

RESULTS:

Microbiological Analysis:

#### Initial count:

Microorganism	Concentration (Initial count)		
Staphylococcus aureus ATCC*6538	2 *108		
Pseudomonas Aeruginosa ATCC®9027	3*10 <sup>9</sup>		
Escherichia Coli ATCC®8739	1*108		
Candida albicans ATCC®10231	1*107		
Aspergillus nigar ATCC® 16404	1*108		
Propionibacterium Acnes ATCC® 6919	6.9*108		
Staphylococcues Epidermidis ATCC®35984	1*108		
MRSA ATCC® BAA-976	3*109		
Streptococcus Pyogenes ATCC®19615	1*108		
MDR ATCC® BAA-2469	1*109		

Ser

IP1.TM-1021a Rev # 07 Page **1** of **3** 

Telefax: 00962 6 515 11 33

E-mail: director@interpharma-1.com P.O.Box: 1416 Amman 11947 Jordan

TR-092-25



### الشركة الأولى للبحث والتطوير الصيدلاني ذ.م.م.

The First For Pharmaceutical Research & Development L.L.C.

	Microorganism	Sure Wound Care  Contact time		
	Wilcitootganism	30s	60s	1208
1	S.aureus (cfu/ml)	4.7*102	9*101	<10
2	P. Aeruginosa (cfu/ml)	1.5*102	8*101	<10
3	E.coli (cfu/ml)	7*101	<10	<10
4	C.albicans (cfu/ml)	4.6*102	8*101	<10
5	A.nigar (cfu/ml)	1.4*103	1*103	7.8*102
6	P.acnes (cfu/ml)	3.6*102	1*101	<10
7	S.epidermidis (cfw/ml)	1.7*102	<10	<10
8	MRSA (cfu/ml)	3.9*103	1.1 *102	6*101
9	S.pyogenes (cfu/ml)	5*101	<10	<10
10	MDR (cfulml)	1*101	<10	<10

#### **TEST METHOD**

Test method used was EN 13624(yeasticidal activity) + EN13727 (bactericidal activity)

Add 8 parts of test product to 1 part test microorganism and 1 part interfering substance the mixture is allowed to interact for (30s,60s,120s) (contact time) .then, 1 part of this mixture is added to 8 parts neutralizer and 1 part water for 5 min to halt bactericidal and yeasticidal activity .This mixture was then cultured to measure the effectiveness of the product

IP1.TM-1021a Rev # 07 Page **2** of **3**  green green

TR-092-25

Telefax: 00962 6 515 11 33

E-mail: director@interpharma-1.com P.O.Box: 1416 Amman 11947 Jordan



### الشركة الأولى للبحث والتطوير الصيدلاني ذ.م.م.

The First For Pharmaceutical Research & Development L.L.C.

### **Summary**

This product found to be effective to reduce microbial loads after used and left to 30s and 60s and 120s as follow:

Micro Sure Wound Care							
	Microorganism	Contact time/log reduction					
		30s	60s	120s			
1	S.aureus (cfu/ml)	6 log reduction	7 log reduction	8 log reduction			
2	P. Aeruginosa (cfu/ml)	7 log reduction	8 log reduction	9 log reduction			
3	E.coli (cfu/ml)	7 log reduction	8 log reduction	8 log reduction			
4	C.albicans (cfu/ml)	5 log reduction	6 log reduction	7 log reduction			
5	A.nigar (cfu/ml)	5 log reduction	5 log reduction	6 log reduction			
6	P.acnes (cfu/ml)	6 log reduction	7 log reduction	ion 8 log reduction			
7	S.epidermidis (cfu/ml)	6 log reduction	8 log reduction	8 log reduction			
8	MRSA (cfu/ml)	6 log reduction	7 log reduction	8 log reduction			
9	S.pyogenes (cfu/ml)	7 log reduction	8 log reduction	8 log reduction			
10	MDR (cfulml)	8 log reduction	9 log reduction	9 log reduction			

Signature:

Merpharma

Results Interpretation: NA

Reviewed by: Road Stour

R M M d N

Date: 11103/25

Date: 11103125

Notes:

- . The results relate only to the item tested as received and may not represent the original batch
- Uncertainty is provided for the examination detailed in the report above, as requested by the customer.
- Sampling is not performed by InterPharma One
- It is the customer's responsibility to evaluate the compliance of these results to any regulatory requirement
- This report must not be reproduced, except in full, without written approval of InterPharma One
- The report may be viewed by legal authorization bodies (JAS, JFDA)

\* In case of any deviation, testing is done upon customer consultation and the tested item may not represent the original batch

IP1.TM-1021a Rev # 07 Page **3** of **3** 

Telefax: 00962 6 515 11 33

E-mail: director@interpharma-1.com P.O.Box: 1416 Amman 11947 Jordan